menu
    • menu

    Company profile for ImmuneOncia Therapeutics, Inc

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies. W...
    ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies. We have successfully completed a Phase I study of IMC-001 in February 2019 and a global Phase II study is planned. Yuhan Corporation is a South Korea-based healthcare company founded in 1926.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmuneOncia Therapeutics, Inckorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    Wins-tower 6F, 15, Pangyo-ro 228beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do...
    Telephone
    Telephone
    +82 (31) 306-8186
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.immuneoncia.com/immun/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immuneoncia
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO
    ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO

    02 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immuneoncia-announces-interim-results-from-phase-1b-clinical-trial-of-next-generation-cd47-antibody-imc-002-at-asco-2025-302470514.html

    PR NEWSWIRE
    02 Jun 2025
    Share Share
    ImmuneOncia's CD47 Antibody Phase 1 Biomarker Results At ASCO
    ImmuneOncia's CD47 Antibody Phase 1 Biomarker Results At ASCO

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603017832/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023
    ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023

    23 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231023637830/en

    BUSINESSWIRE
    23 Oct 2023
    Share Share
    ImmuneOncia Announces PII Results of PD-L1 Immune Checkpoint Inhibitor at ESMO
    ImmuneOncia Announces PII Results of PD-L1 Immune Checkpoint Inhibitor at ESMO

    05 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221205005006/en

    BUSINESSWIRE
    05 Dec 2022
    Share Share
    ImmuneOncia, WuXi Biologics partner for bispecific antibody development
    ImmuneOncia, WuXi Biologics partner for bispecific antibody development

    29 Dec 2021

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/immuneoncia-wuxi-biologics-bispecific-antibody/

    PHARMACEUTICAL-TECHNOLOGY
    29 Dec 2021
    Share Share
    Korean startup ImmuneOncia enhances biologics portfolio for cancer patients
    Korean startup ImmuneOncia enhances biologics portfolio for cancer patients

    29 Dec 2021

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/35/19526/korean-startup-immuneoncia-enhances-biologics-portfolio-for-cancer-patients.html

    BIOSPECTRUMASIA
    29 Dec 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search